Trial Profile
Hypothesis of Empagliflozin reverses complex metabolic and cardiac disturbances in patients with type-2 diabetes mellitus and chronic failure
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Dec 2018
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 16 Dec 2018 New trial record
- 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association